6533b823fe1ef96bd127f758

RESEARCH PRODUCT

Indomethacin treatment in amphotericin B induced nephrogenic diabetes insipidus.

Thomas HöhlerG. TeuberK H Meyer Zum BüschenfeldeR. Wanitschke

subject

medicine.medical_specialtySide effectVasopressinsIndomethacinProstaglandinDiabetes Insipidus NephrogenicKidneyLeukemia Myelomonocytic AcutePathogenesischemistry.chemical_compoundAmphotericin BInternal medicineAmphotericin BDrug DiscoveryMedicineHumansProstaglandin E2Genetics (clinical)business.industryGeneral MedicineMiddle Agedmedicine.diseaseNephrogenic diabetes insipidusDiuresisEndocrinologychemistryDiabetes insipidusToxicityProstaglandinsTobramycinMolecular Medicinelipids (amino acids peptides and proteins)Femalebusinessmedicine.drug

description

Nephrogenic diabetes insipidus (NDI) is a serious side effect of various drugs. Elevated renal prostaglandin E2 levels have been found in patients with lithium-induced NDI and have been implicated in the pathogenesis. We report the case of a patient who developed NDI following treatment with amphotericin B. Prostaglandin levels were elevated. Indomethacin had an antidiuretic effect and normalized prostaglandin levels.

yearjournalcountryeditionlanguage
1994-10-01The Clinical investigator
10.1007/bf00180544https://pubmed.ncbi.nlm.nih.gov/7865979